Changes appearance
Hydration, texture, pigmentation and wrinkle scores are different outcomes. A cosmetic improvement is not evidence of tissue repair.
Claim review · O-032
Peptide skin, hair and wound-care claims
Skin appearance, hair growth and wound healing are separate outcomes. Route and product category change what evidence can transfer.
Peptide claims for skin, hair and wounds range from modest topical cosmetic evidence to unsupported injectable treatment claims. No category-wide verdict is valid. Each molecule, formulation, route and outcome needs its own evidence record.
GHK-Cu has limited topical evidence but no dependable injected-outcome evidence. Melanotan II can darken skin, yet a visible effect does not establish cosmetic safety and regulators have warned against it. Wound-healing claims often rely on laboratory or animal work rather than controlled clinical outcomes.
Claim separation
Start with the exact outcome
Regrows hair
Follicle measurements, shedding counts and durable visible regrowth are not interchangeable. Human scalp outcomes matter.
Heals a wound
Closure time, infection, scarring and function require clinical assessment in a defined wound type. Laboratory migration assays are indirect.
Works when injected
Injection changes systemic exposure and adds sterility, endotoxin and impurity risks. Topical data cannot answer this claim.
Evidence comparison
Common compounds do not share one verdict
| Compound or class | Claim | What the evidence shows | Main limit |
|---|---|---|---|
| GHK-Cu | Skin quality | Small topical studies and mechanistic evidence; clinical results are mixed | Formulation-specific and low-certainty |
| GHK-Cu or related copper peptides | Hair growth | Laboratory and ex vivo findings | No dependable controlled GHK-Cu scalp-regrowth evidence |
| BPC-157 and TB-500 marketing | Wound or tendon healing | Preclinical-dominant evidence | Animal healing findings do not establish injectable treatment |
| Melanotan II | Tanning | Pigmentation can occur | Visible effect does not establish safety; unlicensed products carry product uncertainty |
Route logic
Why route determines the evidence boundary
The same ingredient name can sit inside products with different exposures and regulatory questions.
Topical cosmetic
External appearance claim
Judge the tested formulation, comparator, measurement, irritation, sensitisation and cosmetic compliance. Do not convert an appearance result into a treatment claim.
Topical medicine
Treatment or prevention claim
Claims about wounds, disease or physiological modification may create a medicinal presentation. Clinical evidence and authorisation questions apply.
Injected product
Systemic exposure
Demand route-specific effectiveness and safety evidence plus product-specific identity, amount, impurities, sterility and endotoxin evidence.
UK boundary
Cosmetic and medicinal claims follow different rules
In Great Britain, cosmetic products have a defined compliance framework. A product presented to treat or prevent disease, or to modify physiological functions through pharmacological, immunological or metabolic action, may fall within medicines law.
Classification depends on the whole presentation. Product names, testimonials, images, implied outcomes and linked instructions all matter. A disclaimer cannot reliably neutralise a treatment claim made elsewhere.
Decision boundary
What remains unknown
- Which topical formulations produce reproducible, patient-important improvements.
- Whether small cosmetic studies generalise beyond their tested products.
- Whether laboratory hair-follicle findings produce durable scalp regrowth.
- Whether experimental peptides improve wound outcomes in controlled human trials.
- The systemic and immune risks of injected copper or healing peptides.
- The identity, amount, impurities, sterility and stability of a particular product.
Appraisal test
What a useful skin, hair or wound study should report
Skin trials should name the complete formulation, comparator, treated area, exposure period and objective measurement method. Hair studies need a defined scalp area, blinded counts or images, adequate follow-up and a distinction between reduced shedding and new growth. Wound studies need the wound type, standard care, infection status, closure criteria, pain, scarring and adverse events.
All three fields need participant-reported outcomes as well as objective measures. Selective before-and-after photographs can mislead through lighting, angle and timing. A credible result also reports withdrawals and irritation, infection or pigment changes.
Evidence trap
Why before-and-after images need controls
Lighting, camera distance, lens, angle, hair styling, skin hydration and time of day can create apparent change. Wounds also change naturally and receive concurrent care. Credible imaging uses a standard protocol, blinded assessment and a prespecified measurement window. Images can illustrate a measured result, but they should not replace a comparator, numerical outcome or adverse-event record.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| PubMed: topical copper tripeptide trial | A small topical study with mixed subjective and objective findings. | It does not establish injected use, hair growth or wound treatment. | |
| PubMed: copper peptide and ex vivo hair follicles | A related copper peptide affected isolated human hair follicles ex vivo. | It is not a controlled clinical GHK-Cu hair-regrowth trial. | |
| ClinicalTrials.gov: topical GHK-Cu wound study | A controlled human wound-research question is registered. | Registration does not establish results or routine treatment. | |
| MHRA: borderline products and GN8 | Current UK criteria for cosmetic and medicinal presentations. | It does not classify an unseen product. | |
| GOV.UK: cosmetic products in Great Britain | The GB cosmetic compliance framework. | Compliance does not prove a clinical benefit. |
Continue the investigation
Read the connected evidence
- the GHK-Cu evidence by routeCompare topical human evidence with the injectable evidence gap.
- the tanning compound with documented warningsSeparate a visible pigmentation effect from overall safety.
- UK peptide regulationCheck current classification by presentation, function and jurisdiction.
- what tests can proveSee why chemical purity does not establish sterility or effectiveness.
Quick answers
Frequently asked questions
Are peptides proven to improve skin?
Some topical peptide formulations have early or modest evidence for specific cosmetic outcomes. No class-wide conclusion applies to every ingredient or product.
Can GHK-Cu regrow hair?
The evidence includes mechanistic and ex vivo work, but dependable controlled human evidence for clinically meaningful GHK-Cu scalp regrowth remains insufficient.
Do healing peptides close wounds faster?
Marketing often relies on laboratory and animal research. Controlled human evidence for experimental injectable products remains inadequate.
Does tanning prove Melanotan II is safe?
No. A visible biological effect establishes activity, not a favourable risk-benefit balance or product quality.
Can a topical study support an injection?
No. Formulation, route, exposure and product risks differ, so injected claims need injected human evidence.
What remains unknown?
Reproducible clinical benefits, long-term systemic risks and the identity and quality of individual products remain uncertain.
Editorial experience
From our work: how we checked this page
For topical-map item O-032, Peptide skin, hair and wound-care claims was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 7 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.